Ranbaxy shares recover on value buying after steep falls

Shares in Ranbaxy Laboratories gain as much as 3.3 percent, after falling 26 percent over Friday and Monday following a ban by U.S. drug regulator on more of its products.

"Valuation wise, the stock looks good at these levels. It has fallen a lot and I don't think it will fall beyond 300 rupees," said Suresh Parmar, head, institutional equities at KJMC Capital Markets.

At 10:34 a.m., shares in Ranbaxy were up 2.41 percent at 316.60 rupees, outperforming the broader Nifty, which was up 0.24 percent.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Changes to insurance law will shift market paradigm by several notches

    There is little doubt that the insurance sector is in urgent need of reforms.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Varun Dutt

<b>Riskfactor</b>: THE EMPATHY GAP

The empathy gap (also known as the hot-cold empathy gap) ...

Zehra Naqvi

A thrilling journey

Amrita Chowdhury could well be India’s Jeffery Archer. Edge-of-the-seat thriller ...

Bubbles Sabharwal

Time to gift ourselves some good cheer

The other day, my labrador Cesar asked me, “You do ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture